We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
1 own
8 watching
Current Price
$0
$0.71
(1.79%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
2,856.23M
52-Week High
55.5799
52-Week Low
25.01
Average Volume
0.01M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,856.23M
52-Week High55.5799
52-Week Low25.01
Average Volume0.01M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the company's product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
24days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire NEW YORK, Nov. 4, 2022 NEW YORK, Nov. 4, 2022 /PRNewswire...
Zolmax
1month ago
ProShare Advisors LLC trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT Get Rating) by 34.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,449 shares of the ...
Globe Newswire
1month ago
NEW YORK, Oct. 22, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTC or the Company) (NASDAQ:PTCT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation ...
PR Newswire
3 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its...
PR Newswire
4 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.71
(1.79%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00